Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This study found that adalimumab treatment led to regression of lesions in two patients with hidradenitis suppurativa after 16 weeks of therapy.

This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.

This case report describes a female patient with ankylosing spondylitis who developed generalized pustular psoriasis after adalimumab therapy, and whose condition improved following treatment with secukinumab and acitretin.

This study found that Janus kinase inhibitors were effective in inducing clinical and biochemical remission in patients with Ulcerative Colitis while exhibiting an expected safety profile, though 30% discontinued treatment due to adverse events or lack of efficacy.

Adalimumab improved folliculitis decalvans in most patients.

In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.

In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This case study reports that adding adalimumab to a 12-year-old VKH patient's treatment allowed for ocular inflammation remission, vision improvement, and corticosteroid tapering, suggesting escalation of immunosuppression may be critical in pediatric VKH cases.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

This study reviews the role of semaglutide in obesity management, emphasizing its substantial weight-loss and metabolic benefits in diverse patients, with a focus on its mechanisms, dosing, efficacy, and safety.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

This article describes a case of hypertrichosis potentially induced by using efalizumab but provides no new clinical study results.

This report reviews peer-reviewed case studies indicating potential efficacy of ustekinumab for treating challenging forms of psoriasis but notes the need for further research on cost-effectiveness and risk-benefit.

This case report describes a young woman with ankylosing spondylitis who developed a severe paradoxical skin reaction after six months on certolizumab, requiring treatment with secukinumab and methotrexate.

This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

This document provides a legal disclaimer and offers no research findings.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

This study found that ankylosing spondylitis patients who are members of a self-help organization tend to have higher educational levels, are better informed about their disease, and have better functional outcomes than non-members, although potential confounders may affect disease outcome measures.